David R. Bauer

Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of Insulet Corporation. The offering resulted in approximately $500…

Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $50 million gross sales price of…

Davis Polk advised the joint book-running managers, in connection with an SEC-registered offering by Zoetis Inc. of $750 million aggregate principal amount of its 2.000% senior notes due…

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.0 billion aggregate principal amount of its 2.250% notes due 2050…

Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered common stock and pre-funded warrants offering by Aeglea, including the full exercise…

Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.250% senior notes due 2030…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million aggregate principal amount of its 0.375% convertible senior notes due…

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…